Filing Flows › Silence Therapeutics (SLN) › Q1 2025
Silence Therapeutics (SLN) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Silence Therapeutics (SLN) reported revenue of $142K for the first quarter 2025 (Q1 2025), -99% from a year earlier and -99% from the quarter before.
Silence Therapeutics, Q1 2025: revenue $142K (-99% year over year), net loss $28.5M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $142K | -99% | -99% |
| Operating profit | −$28.4M | — | — |
| Net earnings | −$28.5M | -332% | — |
| Operating cash flow | −$12.3M | — | — |
What changed
Revenue was $142K in Q1 2025, down 99% year over year and down 99% from the previous quarter.
Gross margin was 62.0%, down 20.2 points from a year earlier. Operating costs exceeded revenue by $28.4M, an operating margin of -20006.3%. Operating expenses grew 54% against a revenue fall of 99%. The fastest-growing cost line was Research & development (+76%). The quarter ended with a net loss of $28.5M, after a profit of $12.3M the previous quarter.
Operating cash flow was −$12.3M. Non-cash charges added back $73K of depreciation and $3.5M of share-based compensation. Working capital and other items added $12.6M. Capital expenditures of $4K exceeded it, leaving free cash flow of −$12.3M.
Questions
What was Silence Therapeutics' revenue in the first quarter 2025?
Silence Therapeutics (SLN) reported revenue of $142K for the first quarter 2025 (Q1 2025), -99% from a year earlier and -99% from the quarter before.